NASDAQ · RVMD
Revolution Medicines, Inc.
Healthcare · Biotechnology
$191.31▲ 0.55% ($1.04)at close
Pre-market$191.00▼ 0.16%8:02 AM ET
Valuation
Revenue & margin DCF
A cash-flow estimate wouldn't be reliable here
Need current revenue and shares outstanding to build the revenue-driven FCFF model.
Only 3 of the five annual revenue periods are available; growth uses the observed fiscal-year spans.
Data notes
Only 3 of the five annual revenue periods are available; growth uses the observed fiscal-year spans.
- 10-yr revenue CAGR
- —
- Ending operating margin
- —
- Discount rate
- —
USD · Price used $191.31 · Price Oct 30, 8:00 PM UTC
What each scenario assumes. Click a column to start from it.
Price vs Fundamentals
Why The Stock Is Moving
What changed
The stock rose 224.97% over the last year. Free cash flow declined 75.93% over the trailing twelve months.
What the market seems to be pricing
The stock has moved higher against modestly weakening underlying metrics. The operating data does not yet tell a clear story — the move may reflect sentiment, sector rotation, or macro factors rather than company-specific earnings power.
What would invalidate this read
A decisive shift in revenue or free cash flow over the next period would be the clearest signal to resolve the ambiguity.
Return analysis
Company profile
Revolution Medicines, Inc. is a precision oncology firm operating in the clinical development stage, dedicated to creating innovative treatments that target novel pathways crucial for RAS-driven cancers.
Market multiples
Stock splits
No stock splits recorded for this ticker.
Profitability & growth
Analyst consensus
23
Buy
2
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Actuals vs estimates by quarter, or any quarter against the same one a year earlier.
Next report
Nov 4, 2026
Q3 FY26 · EPS est -$2.35 · Revenue est $25.6M
Q2 FY26
Reported Aug 5, 2026 · Latest
HoverTap a quarter to inspect
Actual
-$3.06
Estimate
-$2.04
Year over year
n/m
Vs prior quarter
n/m
4 misses in the last 4 quarters
Institutional Sentiment
Revolution Medicines, Inc. · RVMD
From Form 13F filings (managers with $100M+). Filings land up to 45 days after quarter end — read this as positioning context, not live fund flow.